Business
Endonovo Therapeutics Announces Issuance of U.S. Patent on Production of Human Biomolecules
Endonovo Therapeutics Announces Issuance of U.S. Patent on Production of Human Biomolecules.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n \n \n Endonovo Therapeutics Announces Issuance of U.S. Patent on Production of Human Biomolecules\n \n \nEndonovo Therapeutics Announces Issuance of U.S. Patent on Production of Human Biomolecules\n\nKey Patent Covers Production of Human Proteins Used as Biologics, including EPO, G-CSF, GM-CSF, and IL-2\n\n \n LOS ANGELES, CA--(Marketwired - Aug 9, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV), a developer of bioelectronic devices and non-invasive Electroceuticals for the treatment of inflammatory conditions in vital organs, announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,410,143 covering the use of electromagnetic stimulation of cells to produce biological molecules. This newly-issued patent covers the production of human biomolecules commonly used as biologics, including EPO, G-CSF, GM-CSF, and IL-2.\n The system and process protected by the patent covers the production of therapeutic proteins by stimulating adult stem cells using the Company's proprietary Time-Varying Electromagnetic Field (TVEMF) technology in a proprietary three dimensional bioreactor system. The technology is part of Endonovo's Cytotronics™ platform, which harnesses the bulk electrical properties of tissues and cells, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic properties of cell therapies and to produce human biomolecules.\n Biopharmaceuticals, also known as biologics, are pharmaceutical drug products manufactured in, extracted from, or semi-synthesized from biological sources. These drugs differ from traditional chemically synthesized drugs and include vaccines, hormones, blood components, recombinant therapeutic proteins and living cells used in cell therapies. Biologics are commonly used to stimulate the growth of specific blood cell types, such as red and white blood cells, and to mobilize blood stem cells from the bone marrow into the bloodstream allowing for their collection and subsequent transplantation into patients following chemotherapy.\n Generating sales of approximately US$6 billion in 2014, and with recent and upcoming patent expirations on a number of biologics by the year 2020, first and next-generation G-CSF products commonly used in the treatment of chemotherapy-induced neutropenia, represent an attractive market for biosimilar and biosuperio...